Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics

The treatment landscape for hemophilia A and B is expanding with strategies and therapies to optimize efficacy, provide durable hemostasis restoration, and improve safety. These contemporary approaches to care have also led to new pathways and assays for clinical and laboratory monitoring.

In this live activity, an interdisciplinary faculty, including a renowned patient advocate who has lived with hemophilia for many years, discuss the impact of key advances in treatment and monitoring on quality of care and outcomes. A focused segment on shared decision making (SDM) keeps the conversation grounded in counseling and collaboration, and includes both clinician and patient perspectives.

At the conclusion of this activity, learners will be able to better:

• Assess the clinical efficacy, durability in restoring hemostasis, and safety of anti-TFPIs and FVIII mimetics for the management of hemophilia
• Develop a clinical and laboratory monitoring plan of the hemostatic status in patients receiving anti-TFPIs and FVIII mimetics
• Implement SDM strategies to engage patients/caregivers with hemophilia in their treatment plan

Supported by an educational grant from Novo Nordisk, Inc.

Hematologists, hematologist/oncologists, nurse practitioners (NPs), physician associates (PAs), and other clinicians involved in the care of patients with hemophilia.

Dr. Shapiro reports the following financial relationships:

Advisory Board: Be Biopharma; CSL Behring; Genentech, Inc./Roche; Novo Nordisk; Pfizer Inc.; Sanofi-Genzyme/Bioverativ Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Consultant: Kedrion Biopharma Inc. and Novo Nordisk

Research Support: Genentech, Inc./Roche; Kedrion Biopharma Inc.; Novo Nordisk; Pfizer Inc.; Sanofi-Genzyme and Kedrion Biopharma Inc.

Speakers Bureau: Genentech, Inc./Roche; Kedrion Biopharma Inc.; and Sanofi-Genzyme

Ms. Bloomberg reports the following financial relationships:

Advisory Board: Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Bayer; Genentech, Inc.; Novo Nordisk; and Sanofi

Mr. Skinner reports the following financial relationships:

Advisory Board/Governance Boards: Blue Cross Blue Shield MAP; Institute for Clinical and Economic Review (ICER); National Organization for Rare Disorders, Inc. (NORD); Pfizer inc. (DSMB); Spark Therapeutics, Inc. (DSMB); and World Federation of Hemophilia USA (WFH USA)

Consultant: National Bleeding Disorders Foundation (NBDF)

Research Support: Mr. Skinner’s institution received research support for the PROBE Study and core outcomes studies as part of independent investigator-initiated research projects: Band Therapeutics, LLC; Bayer; BioMarin; CSL; Novo Nordisk; Roche/Genentech, Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Vega Therapeutics Inc.

Dr. Wheeler reports the following financial relationships:

Advisory Board: Bayer; CSL Behring; Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and Vega Therapeutics Inc.

Research Support: Octapharma Plasma

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Warren Beckman (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

MM-139-040524-68